Comparative Pharmacology
Head-to-head clinical analysis: BREO ELLIPTA versus OTOBIOTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREO ELLIPTA versus OTOBIOTIC.
BREO ELLIPTA vs OTOBIOTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Otobiotic is a fixed-dose combination of ciprofloxacin (a fluoroquinolone antibiotic) and fluocinolone acetonide (a corticosteroid). Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, leading to bacterial DNA replication inhibition and cell death. Fluocinolone acetonide suppresses inflammation by binding to glucocorticoid receptors, modulating gene expression, and reducing inflammatory mediators.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
Adults and children: 3-4 drops into the affected ear twice daily for 7 days. Shake well before use.
None Documented
None Documented
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Terminal elimination half-life: 2-3 hours in patients with normal renal function; prolonged to 24-48 hours in anuria.
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Renal elimination of unchanged drug: 60-80%; biliary/fecal elimination: 10-20%; the remainder undergoes hepatic metabolism.
Category C
Category C
Corticosteroid/Beta-2 Agonist Combination
Otic Antibiotic/Corticosteroid